drugset / Trial / NCT06238024
Effect of Interleukin-6 Receptor Inhibition in Patients With Ischemic Stroke Undergoing Endovascular Treatment
Phase 2/3
Completed
108 enrolled
Suzhou Municipal Hospital of Anhui Province
Xuanwu Hospital, Beijing · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Tocilizumab may exert neuroprotective effects in patients with ischemic stroke undergoing endovascular treatment
Timeline
- Start
- 2024-02-02
- Primary completion
- 2024-06-25
- Completion
- 2024-09-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tocilizumab | Monoclonal antibody | 240 mg | Intravenous |